Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
First and only PARP inhibitor to improve invasive disease-free survival in patients
Strengthens investment in channels of the future to expand patient reach
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Subscribe To Our Newsletter & Stay Updated
